Swipe Left For English News 1 端到端生物药绿色解决方案，助力全球客户可持续发展，为行业贡献积极力量 2 贯穿生物药研究、开发、生产完整生命周期，致力于推动绿色可持续运营 3 运用精益管理和数字化工具，持续改进、追求卓越 4 构建节能减碳技术全景生态，汇聚全球基地节能减碳最佳案例 上海, 2025年9月9日 全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）近日在其首届CRDMO+ Open Day活动上发布《药明生物Green CRDMO白皮书》，分享端到端生物药绿色解决方案，推动全球生物药行业供应链可持续发展。去年11月，公司的Green CRDMO解决方案成功入选联合国全球契约组织（UNGC）“二十年二十佳企业可持续发展案例”，这是制药行业唯一获此殊荣的案例。 《药明生物Green CRDMO白皮书》全球首发 见证嘉宾：药明生物首席执行官陈智胜博士， 药明生物全球生产业务部负责人、高级副总裁郭薇博士， 药明生物首席运营官、高级副总裁俞丽华女士 《药明生物Green CRDMO白皮书》系统阐述了公司应对可持续发展及气候变化的战略方针，同时详尽展现药明生物在生物药研究、开发和生产环节的绿色创新技术及公司绿色可持续运营的节能减碳成果。此《白皮书》共汇聚242个优秀节能案例，覆盖生物制药行业12大能源系统及5大关键节能场景，运用25类节能技术。 此外，药明生物积极探寻精益管理与数字化工具与可持续发展的有效融合，旨在提升资源和能源利用效率，持续提升卓越运营水平。2024年，公司超90%已完成的精益改善项目均实现了经济效益和环境效益的双丰收，收获减碳、节水、降废等改善成果。 药明生物深知应对气候变化的重要性，为此制定了应对气候变化的综合战略、科学可量化的目标矩阵以及清晰路线图。近期，药明生物推出更具雄心的碳减排目标矩阵，获得科学碳目标倡议（SBTi）认证，这也将进一步激励公司坚定不移地应对气候变化，并引领行业向净零经济转型。 陈智胜 博士 药明生物首席执行官 ESG委员会主席 我们欣喜地见证《药明生物Green CRDMO白皮书》的发布，希望凭借我们的科学洞见与优秀实践，为整个行业的可持续发展添砖加瓦。作为全球生物药绿色解决方案领域的领军者，我们始终追求卓越的ESG表现，赋能全球合作伙伴，并与所有利益相关方携手推动价值链负责任发展。 作为联合国全球契约组织（UNGC）和制药供应链倡议组织（PSCI）成员，药明生物积极倡导可持续发展的战略举措并赢得业界广泛认可。公司获得明晟（MSCI）最高AAA ESG评级、EcoVadis“铂金”评级、入选道琼斯可持续发展指数（DJSI）；荣登CDP水安全管理A级榜单和CDP“供应商参与度”A级榜单、获得CDP气候变化A-领导力评分；获评晨星Sustainalytics ESG“风险可忽略”最高评级以及“行业最高评级”与“区域最高评级”企业；入选富时社会责任指数系列；入选恒生ESG 50指数；ISS ESG评级“最佳”奖章认可，充分彰显了公司在可持续发展领域的卓越表现。 请点击文末阅读原文， 下载《药明生物Green CRDMO白皮书》 关于药明生物 药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。 药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2025年6月底，药明生物帮助客户研发和生产的综合项目高达864个，其中包括24个商业化生产项目。 药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。更多信息，请访问：www.wuxibiologics.com ESG esg@wuxibiologics.com 媒体关系 PR@wuxibiologics.com WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry 1 End-to-end Green CRDMO solutions to enable global clients for broader positive impact 2 Span from biologics research, development, manufacturing, and overall operations 3 Integration with lean management and digitalization for continuous excellence 4 A comprehensive ecosystem featuring diverse energy-saving and carbon-reduction initiatives Shanghai, September 9, 2025 WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), recently launched the "WuXi Biologics Green CRDMO White Paper" at its first CRDMO+ Open Day event, sharing the end-to-end Green CRDMO solution for biologics and driving the sustainable development of the global biologics industry supply chain. Last November, the company's Green CRDMO solution was also featured in the "20 Case Examples for 20 Years" report initiated by the United Nations Global Compact, making it the only case in the pharmaceutical industry to receive this honor. Along with an overall introduction to the company's strategic approach toward sustainability and climate change, the White Paper details WuXi Biologics' green innovation technologies across the research, development and manufacturing of biologics, and showcases the significant carbon reduction achieved through green operations. A total of 242 energy-saving cases are compiled in the White Paper, spanning five key energy-saving scenarios, 12 typical energy systems, and 25 technology categories within the industry. In addition, the paper highlights how the integration of lean management and digitalization with sustainability enhances resource and energy efficiency, while driving continuous improvement. In 2024, over 90% of the company's completed Kaizen projects achieved ESG benefits, including reductions in carbon emission, water consumption and waste generation. With a deep understanding of the importance of tackling climate change, WuXi Biologics has adopted a comprehensive, integrated strategy with measurable targets and a well-defined roadmap. Recently, the company announced a new target matrix approved by SBTi, an acknowledgement that further inspires its steadfast dedication to leading the way to a net-zero economy. Dr. Chris Chen Chief Executive Officer Chairman of the ESG Committee WuXi Biologics We are pleased to release the Green CRDMO White Paper with the aspiration that our insights and best practices will inspire and empower the whole industry to drive sustainable progress. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions, and work together with all stakeholders to deliver meaningful and far-reaching impacts. As a participant of the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security "A List" and Supplier Engagement Assessment "A List", and awarded a CDP Climate Change leadership-level "A-" score for two consecutive years; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating. About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing. WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain. For more information about WuXi Biologics, please visit: www.wuxibiologics.com Contacts ESG esg@wuxibiologics.com Media PR@wuxibiologics.com 注：本信息不构成药明生物的信息披露或投资建议 请点击右下角【爱心】， 并将公众号设为【星标】， 第一时间收到药明生物最新消息 点击下方“阅读原文” 下载《药明生物Green CRDMO白皮书》
Swipe Left For English News 注：本信息不构成药明生物的信息披露或投资建议 请点击右下角【爱心】， 并将公众号设为【星标】， 第一时间收到药明生物最新消息 点击下方“阅读原文” 下载《药明生物Green CRDMO白皮书》
<END>
*版权声明：本网站所转载的文章，均来自互联网，旨在传递更多信息。鉴于互联网的开放性和文章创作的复杂性，我们无法保证所转载的所有文章均已获得原作者的明确授权。如果您是原作者或拥有相关权益，请与我们联系，我们将立即删除未经授权的文章。本网站转载文章仅为方便读者查阅和了解相关信息，并不代表我们认同其观点和内容。读者应自行判断和鉴别转载文章的真实性、合法性和有效性。
相关资讯
- 综合
十五载磨一剑，这位科学家说：让中国生物药，既用得上也用得起
抗体圈
2026-06-18
加盟安科生物，共建下一代生物药创新体系，实现长期科学价值！
安科生物
2026-06-16
中药失守，生物药翻倍！中国实体药店最新成绩单出炉，华润领跑
摩熵医药
2026-06-08
2025年中国药品销售全景报告：华润领跑、生物药五连增、抗感染药持续萎缩
摩熵医药
2026-06-08
美参议院考虑ABLA路径，生物药版ANDA在路上
识林
2026-06-01
已上市生物药，不在数据保护范围内
研发客
2026-05-30
生物药出海遇阻？FDA合规红线与辅料策略一次讲清
蒲公英Biopharma
2026-05-23
聚焦FDA警告信：生物药全生命周期合规
蒲公英Biopharma
2026-05-13
拆解FDA警告信: 生物药研发至商业化
蒲公英Biopharma
2026-05-01
生物药、大分子持续爆发，小分子真的日落西山了吗？
盖德视界
2026-04-27
全球药物研发中心
全球研发数据与行业前沿情报
387,986个
全球在研药物数
2,026个
本月临床试验数
研发动态
相关报告
政策法规
-
2026-09-17
-
2026-09-17
-
2026-09-17
-
摩熵咨询 20 7
-
摩熵咨询 20 11
-
摩熵咨询 34 48
-
颁布机构：国家药品监督管理局 2026-09-10
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
最新资讯
- 30年空白终结！拜耳非奈利酮获FDA批准，1型糖尿病相关肾病迎来首个新药，UACR直降25%
- 康方生物第4款ADC获批临床：EGFR/Trop2双抗ADC新药AK158D1剑指晚期恶性实体瘤
- 2026蓝皮书｜CGT未来3-5年研判：技术演进、适应症梯队、国内企业能力框架
- 2026全球CGT交易与投融资分析：交易数量、资产阶段、中美地区分布与活跃机构
- 2026全球与中国CGT市场规模及竞争格局：上市产品、销售额、中外企业对比
- 2026全球与中国CGT管线及临床试验：技术分布、临床进展与地域格局
- 2026细胞与基因治疗（CGT）行业深度概览：技术边界、研发规律与国内监管新格局
- 天士力中药1.1类新药青术颗粒NDA获CDE受理，国医大师经验方冲击急性痛风性关节炎市场
全球新药治疗领域统计
全球新药靶点统计
添加收藏
新建收藏夹
取消
确认
对不起，您今日剩余下载额度不足，请明日再来！
返回
对不起！您还未登录！请登录后查看
收藏
登录后参与评论
暂无评论